A leading life sciences company has confirmed it will harness cloud technology from Amazon Web Services (AWS) to support its efforts to detect cancer early.
California-headquartered GRAIL strives to facilitate the early detection of cancer, while it can still be treated, by combining genomics sequencing, machine learning and data science to ‘transform the way cancer is diagnosed’. It joins the likes of Novartis and Merck in running its cloud infrastructure from AWS.
Ken Drazan, Chief Business Officer at GRAIL, said: “In today’s complex and competitive global healthcare marketplace, technology is a cornerstone in our effort to develop solutions that detect cancer at its earliest stages. AWS’s cloud platform provides critical infrastructure as we scale our databases and computational tools to support our large population-scale clinical studies and the development of our early detection products.”